Biomarin Begin Period Cash Flow vs Net Income Analysis

BMRN Stock

USD 65.42 0.54 0.83%

Biomarin Pharmaceutical financial indicator trend analysis is way more than just evaluating Biomarin Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biomarin Pharmaceutical is a good investment. Please check the relationship between Biomarin Pharmaceutical Begin Period Cash Flow and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Begin Period Cash Flow vs Net Income

Begin Period Cash Flow vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biomarin Pharmaceutical Begin Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Biomarin Pharmaceutical's Begin Period Cash Flow and Net Income is 0.13. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of Biomarin Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Biomarin Pharmaceutical's Begin Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Biomarin Pharmaceutical are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Begin Period Cash Flow i.e., Biomarin Pharmaceutical's Begin Period Cash Flow and Net Income go up and down completely randomly.

Correlation Coefficient

0.13

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Biomarin Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Biomarin Pharmaceutical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Biomarin Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Tax Provision is very stable compared to the past year. As of the 29th of November 2024, Enterprise Value Over EBITDA is likely to grow to 62.44, while Selling General Administrative is likely to drop about 246.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	1.4B	1.6B	1.8B	1.9B
Total Revenue	1.8B	2.1B	2.4B	2.5B

Gross Profit Total Revenue

Biomarin Pharmaceutical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock Total Equity	Short Term Investments	Short Term Debt
Total Assets		0.65	0.77	0.86	1.0	0.97	0.59	-0.36	0.55	0.74	0.99	0.32	0.69	0.94	0.76	0.69	0.96	0.88	0.98	0.97	0.95	0.97	0.48	0.75	0.56	0.12
Short Long Term Debt Total	0.65		0.42	0.45	0.6	0.69	0.32	-0.5	0.46	0.84	0.58	0.25	0.91	0.5	0.84	0.8	0.51	0.7	0.67	0.74	0.54	0.7	0.42	0.82	0.53	0.27
Other Current Liab	0.77	0.42		0.53	0.81	0.63	0.27	0.26	-0.08	0.62	0.75	0.19	0.41	0.8	0.41	0.47	0.81	0.67	0.65	0.64	0.85	0.76	-0.05	0.4	0.22	-0.07
Total Current Liabilities	0.86	0.45	0.53		0.84	0.85	0.5	-0.37	0.68	0.61	0.82	0.16	0.49	0.89	0.55	0.31	0.89	0.82	0.85	0.85	0.83	0.87	0.38	0.57	0.44	0.33
Total Stockholder Equity	1.0	0.6	0.81	0.84		0.96	0.56	-0.29	0.5	0.72	0.98	0.31	0.65	0.96	0.72	0.65	0.97	0.88	0.97	0.94	0.97	0.96	0.43	0.71	0.52	0.08
Property Plant And Equipment Net	0.97	0.69	0.63	0.85	0.96		0.63	-0.54	0.69	0.71	0.96	0.29	0.73	0.9	0.82	0.72	0.91	0.9	0.99	0.97	0.89	0.94	0.6	0.8	0.63	0.12
Net Debt	0.59	0.32	0.27	0.5	0.56	0.63		-0.5	0.41	0.06	0.63	0.16	0.48	0.47	0.61	0.58	0.51	0.35	0.63	0.64	0.49	0.5	0.63	0.59	0.78	-0.3
Retained Earnings	-0.36	-0.5	0.26	-0.37	-0.29	-0.54	-0.5		-0.85	-0.27	-0.35	-0.07	-0.59	-0.19	-0.66	-0.52	-0.19	-0.35	-0.53	-0.52	-0.17	-0.35	-0.79	-0.64	-0.65	-0.19
Accounts Payable	0.55	0.46	-0.08	0.68	0.5	0.69	0.41	-0.85		0.4	0.54	0.26	0.5	0.46	0.62	0.37	0.45	0.56	0.67	0.66	0.41	0.53	0.76	0.63	0.49	0.4
Cash	0.74	0.84	0.62	0.61	0.72	0.71	0.06	-0.27	0.4		0.66	0.26	0.77	0.68	0.65	0.63	0.67	0.8	0.71	0.77	0.69	0.82	0.21	0.64	0.33	0.49
Non Current Assets Total	0.99	0.58	0.75	0.82	0.98	0.96	0.63	-0.35	0.54	0.66		0.41	0.62	0.91	0.75	0.69	0.93	0.84	0.97	0.94	0.93	0.92	0.55	0.74	0.52	0.07
Non Currrent Assets Other	0.32	0.25	0.19	0.16	0.31	0.29	0.16	-0.07	0.26	0.26	0.41		0.18	0.16	0.39	0.44	0.19	0.21	0.29	0.35	0.26	0.18	0.52	0.38	-0.05	0.39
Cash And Short Term Investments	0.69	0.91	0.41	0.49	0.65	0.73	0.48	-0.59	0.5	0.77	0.62	0.18		0.53	0.85	0.85	0.54	0.6	0.73	0.79	0.57	0.75	0.5	0.84	0.79	0.17
Net Receivables	0.94	0.5	0.8	0.89	0.96	0.9	0.47	-0.19	0.46	0.68	0.91	0.16	0.53		0.6	0.46	0.99	0.9	0.9	0.87	0.93	0.95	0.26	0.6	0.41	0.13
Common Stock Shares Outstanding	0.76	0.84	0.41	0.55	0.72	0.82	0.61	-0.66	0.62	0.65	0.75	0.39	0.85	0.6		0.87	0.6	0.7	0.81	0.83	0.61	0.73	0.69	0.99	0.64	0.16
Non Current Liabilities Total	0.69	0.8	0.47	0.31	0.65	0.72	0.58	-0.52	0.37	0.63	0.69	0.44	0.85	0.46	0.87		0.48	0.55	0.72	0.76	0.55	0.65	0.65	0.82	0.69	0.0
Inventory	0.96	0.51	0.81	0.89	0.97	0.91	0.51	-0.19	0.45	0.67	0.93	0.19	0.54	0.99	0.6	0.48		0.88	0.91	0.88	0.97	0.95	0.26	0.6	0.44	0.09
Other Current Assets	0.88	0.7	0.67	0.82	0.88	0.9	0.35	-0.35	0.56	0.8	0.84	0.21	0.6	0.9	0.7	0.55	0.88		0.87	0.86	0.83	0.9	0.31	0.68	0.33	0.27
Other Stockholder Equity	0.98	0.67	0.65	0.85	0.97	0.99	0.63	-0.53	0.67	0.71	0.97	0.29	0.73	0.9	0.81	0.72	0.91	0.87		0.98	0.9	0.95	0.59	0.8	0.64	0.12
Total Liab	0.97	0.74	0.64	0.85	0.94	0.97	0.64	-0.52	0.66	0.77	0.94	0.35	0.79	0.87	0.83	0.76	0.88	0.86	0.98		0.87	0.95	0.6	0.82	0.66	0.23
Property Plant And Equipment Gross	0.95	0.54	0.85	0.83	0.97	0.89	0.49	-0.17	0.41	0.69	0.93	0.26	0.57	0.93	0.61	0.55	0.97	0.83	0.9	0.87		0.93	0.29	0.62	0.45	0.07
Total Current Assets	0.97	0.7	0.76	0.87	0.96	0.94	0.5	-0.35	0.53	0.82	0.92	0.18	0.75	0.95	0.73	0.65	0.95	0.9	0.95	0.95	0.93		0.36	0.72	0.59	0.19
Intangible Assets	0.48	0.42	-0.05	0.38	0.43	0.6	0.63	-0.79	0.76	0.21	0.55	0.52	0.5	0.26	0.69	0.65	0.26	0.31	0.59	0.6	0.29	0.36		0.67	0.58	0.13
Common Stock Total Equity	0.75	0.82	0.4	0.57	0.71	0.8	0.59	-0.64	0.63	0.64	0.74	0.38	0.84	0.6	0.99	0.82	0.6	0.68	0.8	0.82	0.62	0.72	0.67		0.62	0.19
Short Term Investments	0.56	0.53	0.22	0.44	0.52	0.63	0.78	-0.65	0.49	0.33	0.52	-0.05	0.79	0.41	0.64	0.69	0.44	0.33	0.64	0.66	0.45	0.59	0.58	0.62		-0.16
Short Term Debt	0.12	0.27	-0.07	0.33	0.08	0.12	-0.3	-0.19	0.4	0.49	0.07	0.39	0.17	0.13	0.16	0.0	0.09	0.27	0.12	0.23	0.07	0.19	0.13	0.19	-0.16

Click cells to compare fundamentals

Biomarin Pharmaceutical Account Relationship Matchups

Biomarin Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.7B	5.8B	6.0B	6.4B	6.8B	7.2B
Short Long Term Debt Total	848.1M	1.1B	1.1B	1.1B	1.1B	575.2M
Other Current Liab	(13.0M)	289.2M	329.4M	330.3M	351.6M	369.2M
Total Current Liabilities	932.5M	492.5M	539.8M	588.9M	1.2B	1.2B
Total Stockholder Equity	3.1B	4.1B	4.3B	4.6B	5.0B	5.2B
Property Plant And Equipment Net	1.0B	1.0B	1.0B	1.1B	1.1B	1.2B
Net Debt	410.7M	426.0M	491.8M	358.5M	340.6M	214.5M
Retained Earnings	(1.7B)	(861.6M)	(925.7M)	(789.2M)	(621.6M)	(652.6M)
Accounts Payable	570.6M	191.4M	193.0M	231.2M	315.5M	331.3M
Cash	437.4M	649.2M	587.3M	724.5M	755.1M	792.9M
Non Current Assets Total	2.7B	3.5B	3.7B	3.6B	3.9B	4.1B
Non Currrent Assets Other	122.0M	142.2M	151.8M	176.2M	125.5M	72.8M
Cash And Short Term Investments	753.8M	1.1B	1.0B	1.3B	1.1B	595.1M
Net Receivables	377.4M	448.4M	373.4M	461.3M	633.7M	665.4M
Common Stock Shares Outstanding	179.0M	191.7M	182.9M	189.0M	191.6M	127.6M
Liabilities And Stockholders Equity	4.7B	5.8B	6.0B	6.4B	6.8B	7.2B
Non Current Liabilities Total	635.2M	1.2B	1.2B	1.2B	713.0M	586.6M
Inventory	680.3M	698.5M	776.7M	894.1M	1.1B	1.2B
Other Current Assets	130.7M	129.9M	110.4M	104.5M	141.4M	148.5M
Other Stockholder Equity	4.8B	5.0B	5.2B	5.4B	5.6B	5.9B
Total Liab	1.6B	1.7B	1.7B	1.8B	1.9B	2.0B
Property Plant And Equipment Gross	1.0B	1.0B	1.8B	1.9B	1.9B	2.0B
Total Current Assets	1.9B	2.3B	2.3B	2.8B	3.0B	3.1B
Accumulated Other Comprehensive Income	20.2M	(16.1M)	14.4M	(3.9M)	(38.6M)	(36.7M)
Intangible Assets	456.6M	417.3M	388.7M	338.6M	294.7M	244.4M
Common Stock Total Equity	178K	180K	182K	184K	211.6K	126.8K
Short Term Investments	316.4M	416.2M	426.6M	567.0M	318.7M	276.3M
Common Stock	180K	182K	184K	186K	189K	133.2K
Other Assets	612.0M	1.6B	1.6B	1.6B	1.8B	1.9B
Long Term Debt	486.2M	1.1B	1.1B	1.1B	593.1M	553.3M
Property Plant Equipment	1.0B	1.0B	1.0B	1.1B	1.3B	1.3B
Other Liab	98.1M	174.3M	113.7M	73.5M	84.5M	81.8M
Net Tangible Assets	2.5B	3.5B	3.7B	4.1B	4.7B	4.9B
Retained Earnings Total Equity	(1.7B)	(1.7B)	(861.6M)	(925.7M)	(833.1M)	(874.8M)
Long Term Debt Total	830.4M	486.2M	1.1B	1.1B	1.2B	730.7M
Capital Surpluse	4.7B	4.8B	5.0B	5.2B	6.0B	3.7B
Long Term Investments	412.0M	285.5M	507.8M	333.8M	611.1M	353.3M

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biomarin Stock

0.62

ELAN

Elanco Animal Health Potential Growth

Pair Corr

Moving against Biomarin Stock

0.88	BHC	Bausch Health Companies	Pair Corr
0.79	EWTX	Edgewise Therapeutics	Pair Corr
0.79	GILD	Gilead Sciences	Pair Corr
0.73	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.59	ESPR	Esperion Therapeutics	Pair Corr

The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.

The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.607

Earnings Share

1.66

Revenue Per Share

14.529

Quarterly Revenue Growth

0.283

Return On Assets

0.03

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Begin Period Cash Flow vs Net Income Analysis

Begin Period Cash Flow vs Net Income

Begin Period Cash Flow vs Net Income Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Net Income

Biomarin Pharmaceutical fundamental ratios Correlations

Biomarin Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biomarin Pharmaceutical fundamental ratios Accounts

Pair Trading with Biomarin Pharmaceutical

Moving together with Biomarin Stock

Moving against Biomarin Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Other Stockholder Equity	+ 0.99	Property Plant And Equipment Net
Inventory	+ 0.99	Net Receivables
Common Stock Total Equity	+ 0.99	Common Stock Shares Outstanding
Other Stockholder Equity	+ 0.98	Total Assets

Accounts Payable	- 0.85	Retained Earnings
Intangible Assets	- 0.79	Retained Earnings
Common Stock Shares Outstanding	- 0.66	Retained Earnings
Short Term Investments	- 0.65	Retained Earnings
Common Stock Total Equity	- 0.64	Retained Earnings
Cash And Short Term Investments	- 0.59	Retained Earnings